News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

iDenta discusses company's efforts to combat the opioid epidemic with product line of testing

IDenta Corp.

iDenta CEO Amichai Glattstein joins Proactive's Natalie Stoberman to share how the company is tackling the opioid epidemic with its forensic science based products. iDenta is a leading detection and forensic science company that uses the latest in science and technology to provide solutions to law enforcement, military, government agencies and other organizations dealing with the demanding and constantly changing challenges of fighting illicit drugs and terrorist threats globally. Contact Details Proactive Investors +1 347-449-0879 na-editorial@proactiveinvestors.com

April 19, 2023 01:13 PM Eastern Daylight Time

Video
Article thumbnail News Release

BioVaxys details shareholder value with retention of Maxim to achieve US stock exchange listing

BioVaxys Technology Corp

BioVaxys CEO James Passin joins Natalie Stoberman from the 35th International Papillomavirus Conference in Washington, D.C. to discuss its latest news of retaining New York City-based Maxim Group as its financial advisor and investment banker. Passin says Maxim will handle strategic planning, assessment of potential strategic alliances and capital requirements, and advising the company with respect to the process of obtaining a listing on a US national stock exchange. BioVaxys is a clinical stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics. The company is advancing vaccines for SARS-CoV-2, SARS-CoV-1, and a pan-sarbecovirus vaccine based on its haptenized viral protein technology, and is planning a clinical trial of its haptenized autologous cell vaccine used in combination with anti-PD1 and anti-PDL1 checkpoint inhibitors that will initially be developed for Stage III/Stage IV ovarian cancer. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

April 19, 2023 01:00 PM Eastern Daylight Time

Video
Article thumbnail News Release

1606 Corp. shares revenue growth and distribution strategy for Brio Nutrition, Truz Singles brands

1606 Corp.

1606 Corp. CEO Greg Lambrecht joins Proactive's Natalie Stoberman to discuss how the company plans to build its product placement and distribution network for its Truz Singles and Brio Nutrition revenue generating brands. 1606 Corp. is an acquisition-based CBD distribution company with over 45 individual retail products. 1606 Corp is aggressively acquiring established CBD companies to capture sufficient revenue to list on the NASDAQ stock exchange. Contact Details Proactive Investors +1 347-449-0879 na-editorial@proactiveinvestors.com

April 19, 2023 12:58 PM Eastern Daylight Time

Video
Article thumbnail News Release

Headline

BioVaxys Technology Corp

BioVaxys CEO James Passin joins Natalie Stoberman from the 35th International Papillomavirus Conference in Washington, D.C. to discuss its latest news of retaining New York City-based Maxim Group as its financial advisor and investment banker. Passin says Maxim will handle strategic planning, assessment of potential strategic alliances and capital requirements, and advising the company with respect to the process of obtaining a listing on a US national stock exchange. BioVaxys is a clinical stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics. The company is advancing vaccines for SARS-CoV-2, SARS-CoV-1, and a pan-sarbecovirus vaccine based on its haptenized viral protein technology, and is planning a clinical trial of its haptenized autologous cell vaccine used in combination with anti-PD1 and anti-PDL1 checkpoint inhibitors that will initially be developed for Stage III/Stage IV ovarian cancer. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

April 19, 2023 12:51 PM Eastern Daylight Time

Video
Article thumbnail News Release

Delivra Health Brands shares company initiatives in the wellness space for Stress Awareness Month

Delivra Health Brands Inc.

Delivra Health Brands President and CEO Gord Davey joins Proactive's Natalie Stoberman to discuss the importance of stress awareness and how the company is contributing to the wellness space. Davey highlights Delivra's products like Dream Water and LivRelief pain relief creams to help relieve stress and anxiety. He also stresses the importance of a sense of community and the company's internal initiatives, such as implementing a health and wellness series, to help employees cope with work-life balance. Davey says Delivra is committed to providing products and resources that help people lead a healthier, more balanced life. Contact Details Proactive Investors +1 347-449-0879 na-editorial@proactiveinvestors.com

April 19, 2023 12:34 PM Eastern Daylight Time

Video
Article thumbnail News Release

Software Effective Solutions "MEDCANA" (OTC: SFJW) Begins Full Crop Cycle Testing and Advances Infrastructure Development in Colombia

Software Effective Solutions Corp.

McapMediaWire -- Software Effective Solutions (OTC: SFWJ ) (“The Company”, “SFWJ”), doing business as MedCana, is pleased to announce that it has begun full crop cycle testing across all five of its recently acquired companies in Medellín, Colombia. The goal of this testing phase is to train personnel, observe crop behavior, and ensure production processes work seamlessly. These tests are being conducted in smaller, controlled greenhouse environments before being scaled up to full production. In addition to the crop cycle testing, MedCana has made significant progress in infrastructure development. Last week, the company finalized road and rainwater management systems, paving the way for earthmoving equipment to begin terracing and preparation for the first phase of the project. "We are extremely happy with the progress we've made in the construction and development of our five companies in Colombia. We see no obstacles and remain satisfied with all results," said Gabriel Diaz, CEO of SFWJ. MedCana's commitment to meticulous analysis and testing of all variables, including wind currents, humidity, soil, pests, and more, is reflected in the success of its initial infrastructure analysis, which has covered geological, hydrological, and environmental factors. The recent acquisition of Tokan Corp's assets, a software company focused on creating an ERP platform for the cannabis industry, and Eko2O S.A.S., a greenhouse design and distribution company, has positioned MedCana for explosive growth in the region. The expertise and industry knowledge of Juan Ricardo Velez, CEO of Eko2O, has also contributed to dramatically decreasing costs for MedCana's subsidiaries in the region. ABOUT SFWJ: Software Effective Solutions/MedCana is a global infrastructure and holding company in the cannabis industry. With a recent acquisition of a software company, MedCana expanded its offering to provide traceability from plant to product. The company's initial focus is on developing clients and companies in Latin America, with an emphasis on Colombia, and forming partnerships with laboratories, research facilities, and hospitals worldwide. As MedCana moves forward with its expansion plans, the company remains committed to delivering on its promise of building a solid foundation for future growth, ensuring the highest quality pharmaceutical cannabis products and raw material for its customers, and maximizing shareholder value. SAFE HARBOR STATEMENT This press release contains forward-looking statements that can be identified by terminology such as "believes," "expects," "potential," "plans," "suggests," "may," "should," "could," "intends," or similar expressions. Many forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results implied by such statements. These factors include, but are not limited to, our ability to continue to enhance our products and systems to address industry changes, our ability to expand our customer base and retain existing customers, our ability to effectively compete in our market segment, the lack of public information on our company, our ability to raise sufficient capital to fund our business, operations, our ability to continue as a going concern, and a limited public market for our common stock, among other risks. Many factors are difficult to predict accurately and are generally beyond the company's control. Forward-looking statements speak only as to the date they are made, and we do not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made. Contact: Jose Gabriel Diaz, CEO www.medcana.net info@medcana.co Contact Details MedCana info@medcana.co Company Website https://www.medcana.net/

April 19, 2023 09:00 AM Eastern Daylight Time

Article thumbnail News Release

iCliniq Expands Telehealth Offerings in U.S. to Include Primary Care Services and Prescriptions

iCliniq

iCliniq, a leading global provider of healthcare resources with operations in the U.S., U.K., UAE, India, Singapore and Germany, has expanded its telemedicine services in the U.S. market to include a new primary care tier, called iCliniq First, available at icliniq.us. This expansion, which offers video and text-based consultations with U.S. physicians, as well as access to prescriptions, builds on the company’s existing second opinion consultation and deep library of original medical content which has already attracted an audience of 15 million U.S. consumers. iCliniq is unique for its combination of affordable access to primary care physicians, prescriptions and its breadth of authoritative, original content authored by top board-certified physicians. These new iCliniq features also present opportunities for pharmaceutical and medical marketers who want to reach a highly-engaged audience of consumers at the point of interest. The company offers marketers 100% share of voice on contextually relevant topics, as well as ways to reach consumers via display, video ads and other sponsored content. “We’re already delivering on huge demand for information and counsel in the U.S. with our second opinion and deep content library,” said Dhruv Suyamprakasam, CEO of iCliniq. “And now, by providing the U.S. market with access to quality, primary telehealth and prescriptions, we can better serve consumers. In addition, we can offer marketers highly targeted and effective ways to reach these high-intent consumers, at the moment they are actively seeking answers.” Under this expansion, iCliniq First now offers real-time and asynchronous consultations with primary care physicians to U.S. audiences via video and text-based health services. iCliniq also now offers prescription writing along with thousands of high-intent medical articles authored by board-certified doctors and healthcare professionals. “As we expand our offerings in the U.S., we are building on the successful model we have provided to other markets around the world because we believe consumers everywhere deserve to have cost-effective and dependable access to healthcare,” Suyamprakasam said. “People with and without insurance need a stress free way to receive care.” iCliniq is certified as a HIPAA-compliant platform, offering the highest level of data protection while also adhering to internationally recognized NIST-security standards. “Being able to review thousands of articles from medical specialists on specific issues and conditions can provide consumers with peace of mind or at least knowledge about what is going on in their bodies,” Suyamprakasam said. “iCliniq First goes a step further and gives consumers a chance to come directly to us at the onset of their issue and get the care they need.” Cliniq, founded in 2012, is the leading global provider of virtual healthcare resources. Its virtual online medical service provides convenient, premier health care to more than 190 countries. iCliniq’s doctor panel consists of more than 3,500 highly-qualified doctors from 80+ specialties in the U.S., U.K., UAE, India, Singapore and Germany. The company is headquartered in Herndon, Virginia and has offices in Coimbatore, Tamil Nadu, India. iCliniq has built a reputation for providing quality medical information and care globally, which led to a partnership with Memorial Sloan Kettering Cancer Center (MSK) to launch MSK in India. Through this partnership, patients get remote second opinion services in India, including pathology and radiology review, genetic sequencing and analysis of cancer, customized written care plan, live video consultation, and integrative medicine. iCliniq has been rated among the top telemedicine portals in the world by CPoE, Parade, and Insider. For more information, visit https://www.icliniq.com/. Contact Details Kite Hill PR for iCliniq Maggie Stasko +1 724-787-1565 icliniq@kitehillpr.com Company Website https://www.icliniq.com/

April 19, 2023 09:00 AM Eastern Daylight Time

Article thumbnail News Release

Algernon Pharmaceuticals receives notice of allowance for US patent for drug Repirinast and NASH

Algernon Pharmaceuticals Inc.

Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news the company has received a Notice of Allowance for a patent around its work on chronic kidney disease. Moreau tells Proactive the patent, which is titled “Compositions and Methods for Treating Non-Alcoholic Steatohepatitis”, is based around its kidney disease program with the drug NP-251 or Repirinast. This is the company’s first allowance notice received from the US patent office. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

April 18, 2023 12:56 PM Eastern Daylight Time

Video
Article thumbnail News Release

La Société canadienne de la schizophrénie reçoit 978 000 $ pour un projet d'éducation sur le cannabis et la santé mentale

The Schizophrenia Society of Canada (SSC)

La Société canadienne de schizophrénie (SCS) est ravie d'annoncer un financement de 978 000 $ de Santé Canada pour soutenir son Projet national sur le cannabis et la santé mentale. Ce financement aidera à combler l'écart dans l'espace de la santé mentale au Canada en veillant à ce que l'information sur les effets du cannabis soit accessible aux jeunes en besoin. Les jeunes Canadiens (15 à 24 ans) ont l'un des taux de consommation de cannabis les plus élevés au monde 1,2 avec des taux de prévalence presque le double de ceux des adultes. La recherche précise l'écart persistant dans la mise en œuvre d'une éducation pertinente sur le cannabis dans divers contextes et ciblée sur des groupes d'âge spécifiques, en particulier les jeunes. Le financement aidera à affiner et à amplifier les ressources innovantes développées par et pour les jeunes dans le cadre de ce projet. Le projet comprend un cours de certificat autodirigé sur le cannabis et la santé mentale, un guide de mentorat, le site Web sur le cannabis et la psychose et de nombreux produits de mobilisation des connaissances axés sur le partage accessible d'expertise scientifique et expérientielle. « Je suis reconnaissante à la Société canadienne de la schizophrénie et à ses partenaires communautaires d'avoir adapté le programme Cannabis et santé mentale pour rejoindre un public plus large de jeunes », a déclaré l'honorable Carolyn Bennett, ministre de la Santé mentale et des Dépendances et ministre associée de la Santé. « Alors que notre gouvernement s'efforce d'améliorer les services de soins de santé intégrés pour tous les Canadiens, ce financement aidera à donner à plus de jeunes les moyens de protéger leur santé mentale et de mieux comprendre les effets sur la santé de la consommation de cannabis.» Le cours sur le cannabis et la santé mentale et les ressources associées sont fondés sur des données probantes et élaborés à partir des expériences vécues et de l'expertise des jeunes, des parents, des éducateurs et des cliniciens. Ce financement permettra au projet Cannabis et santé mentale de continuer à répondre aux besoins des jeunes. De plus, ce financement nous aidera à offrir des formations et des ateliers aux enseignants, cliniciens et autres adultes alliés. "Ce projet est d'une grande importance dû au nombre de jeunes qui consomment du cannabis à des fins récréatives ou pour résoudre des problèmes de santé mentale, et peuvent ignorer qu'il peut comporter des risques. Avec le cannabis et la santé mentale, nous procédons une éducation fondée sur des preuves entre les mains des jeunes, éducateurs et alliés adultes.” Chris Summerville PDG SCS Pour plus d'informations sur le projet Cannabis et santé mentale, visitez: cannabisandmentalhealth.ca et cannabisandpsychosis.ca ou suivez-nous sur LinkedIn, Twitter, Facebook, Instagram et Youtube. Socialpresskit À propos: La Société canadienne de la schizophrénie (SCS) œuvre pour un avenir où les personnes atteintes de psychose précoce et de schizophrénie peuvent réaliser leur potentiel. Cela est possible avec des services de santé mentale axés sur l'intervention précoce et le rétablissement. Le cœur et l'âme du SCS est la conviction que la vie peut être améliorée pour ceux qui souffrent de psychose précoce et de schizophrénie. Témoignages du projet sur le cannabis et la santé mentale: « Ces ressources offrent un programme équilibré, fondé sur des données probantes et engageant sur la relation entre la consommation de cannabis et la santé mentale, afin de donner aux jeunes les outils nécessaires pour prendre des décisions éclairées. Elles créent une excellente ouverture pour explorer pourquoi les jeunes choisissent de consommer du cannabis, l'impact de la légalisation sur diverses communautés, et l'importance d'approches de déstigmatisation et de réduction des méfaits en matière d'éducation à la toxicomanie et à la santé mentale. Julia Armstrong, gestionnaire, Santé mentale et toxicomanie. avril 2023 Le projet Cannabis et santé mentale a été créé par un groupe diversifié de jeunes, y compris ceux ayant des expériences vécues, s'identifiant comme noirs, autochtones ou autres personnes racialisées et provenant de régions géographiquement disparates à travers le Canada. Ces perspectives sont mises en évidence tout au long du cours à travers des conversations entre les jeunes sur leur expérience de la stigmatisation et la perspective d'un jeune autochtone sur la spiritualité. Nous espérons qu'en voyant d'autres comme eux, les jeunes plus difficiles à atteindre, en particulier ceux qui estiment que leurs réalités ne sont pas reflétées par les approches de santé publique traditionnelles en matière de cannabis et de santé mentale, se sentiront plus enthousiasmés et responsabilisés par un contenu accessible et équilibré. Hargun Kaur, Comité national d'action jeunesse, avril 2023. Le cours sur le cannabis et la santé mentale vise à évaluer les besoins de ceux qui existent dans les marges. Le projet adopte une approche basée sur les forces pour prioriser les besoins de communautés spécifiques tout en élevant la voix de ceux qui peuvent être plus à risque d'effacement et d'exclusion. Connor LaFortune, Conseiller stratégique autochtone, avril 2023. Contact Details Sarah Roht, Chef de projet sarah@schizophrenia.ca

April 18, 2023 10:00 AM Eastern Daylight Time

1 ... 118119120121122 ... 290